ADMA — ADMA Biologics Income Statement
0.000.00%
Last trade - 00:00
- $1.45bn
- $1.53bn
- $258.22m
- 74
- 11
- 97
- 64
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 29.3 | 42.2 | 80.9 | 154 | 258 |
Cost of Revenue | |||||
Gross Profit | -10.2 | -19.1 | 1.17 | 35.3 | 88.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 80.7 | 106 | 139 | 200 | 263 |
Operating Profit | -51.4 | -63.9 | -58.4 | -46 | -4.54 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -48.3 | -75.7 | -71.6 | -65.9 | -28.2 |
Net Income After Taxes | -48.3 | -75.7 | -71.6 | -65.9 | -28.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -48.3 | -75.7 | -71.6 | -65.9 | -28.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -48.3 | -75.7 | -71.6 | -65.9 | -28.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.917 | -0.891 | -0.513 | -0.299 | -0.009 |